4. Now let's learn about some of the diseases that may be treated using these genetic medicines. Scroll through the interactive and click on the pink " + "sign that is labeled with the disease. Next, click on the "Case Study" tab at the top to reveal information about the disease. Read the "Case Study" material, watch the video, and read the information in the "Learn more" link. Chose 3 out of the 5 diseases listed bolow and describe how genetic modicine can be used to treat them. A. Leber Congenital Amaurosis B. Sickle Cell Disease C. Duchenne Muscular Dystrophy D. Huntington's Disease E. Cystic Fibrosis

Question

UpStudy AI · Accepted Answer

Genetic medicine, particularly gene therapy, has shown promise in treating various genetic diseases by addressing the underlying genetic mutations. Here’s how genetic medicine can be used to treat three of the diseases listed:

### A. Leber Congenital Amaurosis (LCA)
Leber Congenital Amaurosis is a rare genetic disorder that causes severe vision loss at birth or in early childhood. It is primarily caused by mutations in genes essential for the function of photoreceptor cells in the retina.

**Genetic Medicine Approach:**
Gene therapy for LCA typically involves delivering a healthy copy of the mutated gene directly to the retinal cells. One of the most notable examples is the use of adeno-associated virus (AAV) vectors to deliver the RPE65 gene, which is crucial for the visual cycle. This treatment has been shown to improve vision in patients with specific mutations in the RPE65 gene. The therapy aims to restore the function of the photoreceptors, allowing for improved visual perception.

### B. Sickle Cell Disease
Sickle Cell Disease (SCD) is a genetic blood disorder caused by a mutation in the hemoglobin gene, leading to the production of abnormal hemoglobin (hemoglobin S). This results in distorted, sickle-shaped red blood cells that can cause blockages in blood vessels, leading to pain and organ damage.

**Genetic Medicine Approach:**
Gene therapy for SCD often involves editing the patient's own hematopoietic stem cells (HSCs) to correct the mutation or to induce the production of fetal hemoglobin (HbF), which can replace the defective hemoglobin. Techniques such as CRISPR-Cas9 gene editing can be used to target and modify the specific gene responsible for the disease. By reintroducing these edited cells back into the patient, the hope is to produce healthy red blood cells that do not sickle, thereby alleviating symptoms and reducing complications associated with the disease.

### C. Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy is a severe muscle-wasting disease caused by mutations in the dystrophin gene, which is essential for muscle cell integrity. The absence of dystrophin leads to progressive muscle degeneration and weakness.

**Genetic Medicine Approach:**
Gene therapy for DMD focuses on delivering a functional copy of the dystrophin gene or using techniques to skip over faulty parts of the gene to produce a shorter but functional version of dystrophin. One approach involves using exon-skipping technology, where specific exons of the dystrophin gene are skipped during the mRNA processing, allowing for the production of a partially functional dystrophin protein. This can help stabilize muscle cell membranes and slow the progression of the disease. Additionally, gene editing technologies like CRISPR may also be employed to correct mutations directly in the dystrophin gene.

### Conclusion
Genetic medicine offers innovative approaches to treating genetic diseases by targeting the root causes of these conditions. Through gene therapy, patients with Leber Congenital Amaurosis, Sickle Cell Disease, and Duchenne Muscular Dystrophy may experience significant improvements in their health and quality of life. As research continues, these therapies hold the potential to transform the treatment landscape for many genetic disorders.
Genetic medicine can treat diseases like Leber Congenital Amaurosis, Sickle Cell Disease, and Duchenne Muscular Dystrophy by correcting genetic mutations. For LCA, a healthy gene is delivered to the retina; for SCD, the mutation is edited in stem cells to produce healthy red blood cells; and for DMD, a functional version of the dystrophin gene is produced.

Real Tutor Solution

Answer

Solution

The Deep Dive

Related Questions

Latest Medicine Questions